The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Phase 1 Completed 16 enrolled GlaxoSmithKline

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This A Three-Part Drug-Drug Interaction Study To Evaluate Effects of Casopitant On Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adults

Timeline

Start: 2007-07-23
Primary completion: 2007-09-21
Completion: 2007-09-21

Publications

Results Adams LM, Johnson B, Zhang K, Yue L, Kirby LC, Lebowitz P, Stoltz R. Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer. 2009 Sep;17(9):1187-93. doi: 10.1007/s00520-008-0572-4. Epub 2009 Feb 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Casopitant	Small molecule	50 mg	Oral
Subject	Granisetron	Other / unclassified	2 mg	Oral
Subject	Rosiglitazone	Small molecule	4 mg	Oral
Subject	dolasetron	Small molecule	100 mg	Oral

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Summary

Timeline

Publications

Drugs

Indications